Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

NCT03952325 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

294

Enrollment

INDUSTRY

Sponsor class

Stopped The Sponsor has discontinued the development of tesetaxel

Conditions

Breast Cancer

Interventions

DRUG: Tesetaxel
DRUG: Tesetaxel
DRUG: Tesetaxel
DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Atezolizumab
DRUG: Tesetaxel

Sponsor

Odonate Therapeutics, Inc.